Novartis Venture joins Forendo series A
This article was originally published in Scrip
Forendo Pharma of Finland has raised €12m in a series A financing round. Novartis Venture Fund and Merck Serono (MS) Ventures invested, along with current shareholders Karolinska Development, Novo Seeds and Finnvera.
You may also be interested in...
Emerging Company Profile: Finland's Forendo Pharma hopes an imminent improvement in diagnostic possibilities will eventually help it commercialize a drug for endometriosis, which it believes could enable more effective treatment of a disease that afflicts large numbers of women.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.